The pharmaceutical firm Regeneron on Monday announced it was entering the late stages of its human clinical trials investigating a drug to both treat and prevent COVID-19. The drug, called REGN-COV2, is a combination of two antibodies that block the coronavirus’ “spike protein” which it uses to invade human cells. This trial, run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID), is expected to enroll 2,000 patients in the US.
Read from Source